宣泰医药
(688247)
| 流通市值：15.87亿 | | | 总市值：50.55亿 |
| 流通股本：1.42亿 | | | 总股本：4.53亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 362,608,213.87 | 217,994,634.76 | 111,411,602.18 | 299,871,288.42 |
| 营业收入 | 362,608,213.87 | 217,994,634.76 | 111,411,602.18 | 299,871,288.42 |
| 二、营业总成本 | 266,457,899.41 | 164,678,881.83 | 85,556,447.58 | 245,991,998.67 |
| 营业成本 | 176,822,016.82 | 111,296,496.43 | 60,773,860.34 | 132,264,896.48 |
| 税金及附加 | 1,996,359.69 | 1,168,884.9 | 576,726.51 | 3,031,626.14 |
| 销售费用 | 6,836,662.01 | 4,525,145.85 | 2,194,591.58 | 8,173,684.47 |
| 管理费用 | 27,716,639.75 | 17,503,026.14 | 7,842,106.8 | 35,756,982.28 |
| 研发费用 | 56,471,663.02 | 34,064,136.64 | 15,454,452.53 | 74,005,449.29 |
| 财务费用 | -3,385,441.88 | -3,878,808.13 | -1,285,290.18 | -7,240,639.99 |
| 其中:利息费用 | 2,208.77 | 1,666.2 | 928.65 | 37,811.74 |
| 其中:利息收入 | 3,201,812.22 | 2,280,178.26 | 1,085,809.88 | 6,077,806.09 |
| 加:投资收益 | 6,995,137.82 | 6,356,440.98 | 1,006,800.32 | 11,369,093.27 |
| 资产处置收益 | - | - | - | 82,092.19 |
| 资产减值损失(新) | 122,816.63 | -1,021,254.23 | -63,998.11 | -1,531,527.4 |
| 信用减值损失(新) | -3,420,670.57 | -842,399.91 | -398,975.62 | -805,908.37 |
| 其他收益 | 2,920,413.33 | 1,739,729.12 | 189,044.79 | 6,018,723.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 102,768,011.67 | 59,548,268.89 | 26,588,025.98 | 69,011,763.3 |
| 加:营业外收入 | 5,549.16 | 824.78 | 128.32 | 128,136.26 |
| 减:营业外支出 | 836,057.54 | 292,055.27 | 184,525.4 | 3,149,118.08 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 101,937,503.29 | 59,257,038.4 | 26,403,628.9 | 65,990,781.48 |
| 减:所得税费用 | 9,364,528.57 | 5,103,703.52 | 3,507,723.42 | 4,916,713.41 |
| 六、净利润 | 92,572,974.72 | 54,153,334.88 | 22,895,905.48 | 61,074,068.07 |
| 持续经营净利润 | 92,572,974.72 | 54,153,334.88 | 22,895,905.48 | 61,074,068.07 |
| 归属于母公司股东的净利润 | 92,572,974.72 | 54,153,334.88 | 22,895,905.48 | 61,074,068.07 |
| (一)基本每股收益 | 0.21 | 0.12 | 0.05 | 0.13 |
| (二)稀释每股收益 | 0.21 | 0.12 | 0.05 | 0.13 |
| 八、其他综合收益 | 10,602.66 | -3,507.81 | -107.34 | 17,977.65 |
| 归属于母公司股东的其他综合收益 | 10,602.66 | -3,507.81 | -107.34 | 17,977.65 |
| 九、综合收益总额 | 92,583,577.38 | 54,149,827.07 | 22,895,798.14 | 61,092,045.72 |
| 归属于母公司股东的综合收益总额 | 92,583,577.38 | 54,149,827.07 | 22,895,798.14 | 61,092,045.72 |
| 公告日期 | 2024-10-30 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |